التفاصيل البيبلوغرافية
| العنوان: |
Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison |
| المؤلفون: |
Kroidl, Inge, Winter, Simon, Rubio-Acero, Raquel, Bakuli, Abhishek, Geldmacher, Christof, Eser, Tabea M., Déak, Flora, Horn, Sacha, Zielke, Anna, Ahmed, Mohamed I. M., Diepers, Paulina, Guggenbühl, Jessica, Frese, Jonathan, Bruger, Jan, Puchinger, Kerstin, Reich, Jakob, Falk, Philine, Markgraf, Alisa, Fensterseifer, Heike, Paunovic, Ivana, Thomschke, Angelika, Pritsch, Michael, Riess, Friedrich, Saathoff, Elmar, Hoelscher, Michael, Olbrich, Laura, Castelletti, Noemi, Wieser, Andreas, Alamoudi, Emad, Anderson, Jared, Baldassarre, Valeria, Baumann, Maximilian, Becker, Marc, Bednarski, Franziska, Behlen, Marieke, Bemirayev, Olimbek, Beyerl, Jessica, Bitzer, Patrick, Böhnlein, Rebecca, Brand, Isabel, Brauer, Anna, Britz, Vera, Bünz, Franziska, Caroli, Friedrich, Coleman, Josephine, Contento, Lorenzo, Czwienzek, Alina, Deák, Flora, Diefenbach, Maximilian N, Diekmannshemke, Jana |
| المساهمون: |
Bavarian State Ministry of Science and the Arts, University Hospital, LMU Munich, German Ministry for Education and Research, Euroimmun and Roche provided kits and machines for analyses at discounted rates for the study, European-wide Consortium ORCHESTRA, Universitätsklinik München |
| المصدر: |
Virology Journal ; volume 20, issue 1 ; ISSN 1743-422X |
| بيانات النشر: |
Springer Science and Business Media LLC |
| سنة النشر: |
2023 |
| مصطلحات موضوعية: |
Infectious Diseases, Virology |
| الوصف: |
Background Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization between different quantitative anti-Spike assays to defined Binding Antibody Units (BAU). Methods To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 surrogate virus neutralization. Both cohorts were evaluated using the Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and the Roche Elecsys Anti-SARS-CoV-2 anti-S1 assay. Results In SARS-CoV-2-convalesce subjects, the BAU-sero-responses of Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and Roche Elecsys Anti-SARS-CoV-2 anti-S1 peaked both at 47 (43–51) days, the first assay followed by a slow decay thereafter (> 208 days), while the second assay not presenting any decay within one year. Both assay values in BAUs are only equivalent a few months after infection, elsewhere correction factors up to 10 are necessary. In contrast, in infection-naive vaccinees the assays perform similarly. Conclusion The results of our study suggest that the establishment of a protective correlate or vaccination booster recommendation based on different assays, although BAU-standardised, is still challenging. At the moment the characteristics of the available assays used are not related, and the BAU-standardisation is unable to correct for that. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1186/s12985-023-02167-z |
| DOI: |
10.1186/s12985-023-02167-z.pdf |
| DOI: |
10.1186/s12985-023-02167-z/fulltext.html |
| الإتاحة: |
https://doi.org/10.1186/s12985-023-02167-zTest |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: |
edsbas.929A6536 |
| قاعدة البيانات: |
BASE |
